Slides
Page 1
Draft v4 FY26 Investor Presentation 25 August 2026 Infection prevention. For life. Michael Kavanagh CEO & President Jason Burriss CFO
Page 2
Protecting 31 million patients every year Nanosonics develops transformative technologies in medical device reprocessing to improve patient safety and deliver better health outcomes. 2
Page 3
1. Constant currency removes the impact of foreign exchange rate movements to facilitate comparison of operational performance. Refer to note in Appendix. 3 Solid revenue and earnings growth at constant currency REPORTED REVENUE $203.9M 3% on pcp EBIT $16.0M 10% on pcp 21% CC OPERATING EXPENSES $141.4M GROSS PROFIT % 76.9% 1.3 pts on pcp 2% on pcp $211.5M 6% CC REVENUE AT CONSTANT CURRENCY 1 (CC) GROSS PROFIT % AT CC 0.6 pts on pcp77.6% OPERATING EXPENSES AT CC $143.9M 4% CC EBIT AT CC $21.6M
Page 4
Core trophon-only business profitability growing strongly Generating cash and funding next platform growth. Sustained EBIT growth and high-quality cash conversion in the trophon- only business demonstrates durability and provides self-funded capacity for the next phase of growth. 4 $50.6M 5% on pcp EBIT $56.5M 16% CC EBIT in CC 4
Page 5
FY26 delivery sets up next phase of growth Advancing trophon leadership CORIS moving to launch Scaling operations for growth 5 trophon3 and trophon2 Plus launched, with adoption accelerating in H2. Global cumulative installed base1 grew to 39,230. North American upgrades up 32%, with further 8,000 EPR device upgrade opportunity. Regulatory clearance across UK, Europe and Australia. First US FDA 510(k) approved for expanded scope indications, second submitted. Commercial launch to start in H1 FY27. US consumables manufacturing established. Dedicated CORIS manufacturing line established in Australia. New HQ and manufacturing laboratories registered, move planned for Q3 FY27. Digital capability expansion to support connectivity strategy. Milestones met across trophon leadership, CORIS launch readiness and operational expansion 1. Cumulative sales of new installed base units.
Page 6
Installed base expands and upgrades accelerate Cumulative Installed Base Upgrades Total unit placements • 2,230 new installed base • 6% growth to 39,230 devices 6% growth on pcp (Devices) 1,510 1,660 2,000 FY24 FY25 FY26 34,790 37,000 39,230 FY24 FY25 FY26 20% growth on pcp 3,850 3,870 4,230 FY24 FY25 FY26 9% growth on pcp Graphs are not to scale and therefore not comparable. • 2,000 upgrade units, 20% growth on pcp • Record North America upgrades, up 32% with 1,980 upgrades placed • 4,230 total trophon units placed, up 9%. • Strongest annual placements in three years(Devices) (Devices) 6
Page 7
Growth across both Capital and Recurring revenue Total Revenue Capital Revenue Recurring Revenue 7Graphs are not to scale and therefore not comparable. 6% growth on pcp in CC 3% growth on pcp 8% growth on pcp in CC 4% growth on pcp 48.2 52.5 54.7 56.7 FY24 FY25 FY26 FY26 CC • At constant currency, Capital Revenue of $56.7 million, up 8% (Reported up 4% to $54.7 million). • Growth driven by strong total device placements. • Pricing strengthened through H2 as trophon3 took a larger share of sales. 121.8 146.1 149.2 154.8 FY24 FY25 FY26 FY26 CC 6% growth on pcp in CC (8% excl. spare parts) 2% growth on pcp • At constant currency, Revenue of $211.5M, up 6% delivering solid performance. • Reported Revenue of $203.9 million, up 3%, reflecting the strengthening of AUD during FY26. • At constant currency, Recurring Revenue was $154.8 million, up 6% (Reported up 2% to $149.2 million). • Growth across core consumables, ecosystem products and service. • As expected, spare parts continue to reduce as customers upgrade to newer trophon systems. • In constant currency, Recurring Revenue excluding spare parts (known as Annuity Revenue) was $147.1 million, up 8%. ($M) ($M) ($M) 170.0 198.6 203.9 211.5 FY24 FY25 FY26 FY26 CC
Page 8
Now entering a defining period of long-term growth with second transformational platform Leveraging trophon strengths to build the CORIS business. THE CORIS SYSTEM Transformation potential Strong fundamentals of adoption, with regulatory clearance secured across the UK, Europe and Australia. Phased commercial launch across all regions starting in H1 FY27. Proven trophon foundations support CORIS commercialisation TROPHON Market leading technology, delivering profitability and cash generation. 39,230 devices installed and $154.8 million of Recurring Revenue at CC. Commercial reach Established sales and service infrastructure, and deep customer relationships. Supply and scale Manufacturing and logistics expertise, with consumables production established in the US. Proven commercial model Multiple recurring revenue streams and purchase model flexibility. 8
Page 9
FY26 Financial Results 9
Page 10
A year of constant currency earnings growth, disciplined investment and capital returns • EBIT growth of 21% in constant currency with solid Revenue growth and disciplined operating expense performance. • Continuing operational leverage gains in the trophon- only business. • Investing in the future growth engine of CORIS. • $20 million returned to shareholders with $40 million planned in FY27. 10 10
Page 11
Profit & Loss 11 • Reported Revenue of $203.9 million, up 3%. • Revenue was up 6% at CC, reflecting solid growth across both Capital and Recurring Revenue. • Gross profit of 76.9%, was in line with company expectations moderating by 0.6ppts due to product mix and 0.7ppts due to a stronger AUD vs USD in FY26. FY26 tariffs of $0.6 million, broadly flat on FY25 ($0.5 million). • Operating expenses of $141.4 million, up 2% or 4% at CC, reflecting disciplined cost control while continuing to invest in CORIS • R&D as a percentage of sales easing from 17% in FY25 to 16% in FY26. • EBIT of $16.0 million, down 10% on pcp, or up 21% at CC. • Operating income before income tax of $20.1 million, down 10% on pcp, or up 15% at CC. • Profit after income tax of $17.8 million, down 14% on pcp, or up 13% at CC, with the effective tax rate increasing from 7% in FY25 to 11% in FY26. $ millions FY26 Reported FY25 Reported % growth Reported % growth at CC1 Capital revenue 54.7 52.5 4% 8% Recurring revenue 149.2 146.1 2% 6% Total revenue 203.9 198.6 3% 6% Gross profit 156.8 155.4 1% 6% Gross profit % 76.9% 78.2% -1.3ppts -0.6pts Operating expenses Selling, general and administration 109.6 104.0 5% Research and development 31.8 34.7 -8% Total Operating expenses 141.4 138.7 2% 4% Operating margin 15.4 16.7 -8% 21% Other income 1.5 1.3 16% Other gains/(losses)-net (0.9) (0.1) nm* Earnings before interest and tax 16.0 17.8 -10% 21% Finance income-net 4.1 4.5 -8% Operating income before income tax 20.1 22.3 -10% 15% Income tax expense (2.3) (1.6) Profit after income tax 17.8 20.7 -14% 13% *nm = not meaningful comparison 1. Constant currency removes the impact of foreign exchange rate movements to facilitate comparison of operational performance. The average exchange rate used for the Company's major foreign currency (USD) in FY25 was 0.65 and this exchange rate has been applied to US derived revenue reported today. Due to the strengthening of the AUD, the average USD foreign exchange rate for the full year FY26 was 0.68. Disciplined execution delivering increased EBIT in constant currency
Page 12
48.2 52.5 54.7 56.7 FY24 FY25 FY26 FY26 CC 8% Capital Revenue growth in constant currency, led by record North American placements 12 Capital Revenue up 4% on pcp, or 8% in CC. • Growth driven by higher volumes. • North America remained the key growth driver, with record placements, including record upgrades. • Average selling price strengthened through H2 as trophon3 became a larger proportion of sales. • trophon2 Plus software upgrade contribution increase in Q4 with strong momentum heading into FY27. Graphs are not to scale and therefore not comparable. 4% growth on pcp 8% growth on pcp in CC Capital Revenue
Page 13
8% Annuity Revenue1 growth at constant currency demonstrating quality of the business model 13 Annuity Revenue grew 4% on pcp, or 8% at CC. • Core consumables, flat on pcp, or up 4% at CC, with North America growing 5% at CC. • Ecosystem up 5% on pcp, or 6% at CC, as customers adopt more of the trophon workflow. • Service revenue up 14% on pcp, or up 19% at CC, reflecting continued growth in customers taking up service offerings. Note: Spares parts moderated 22% on pcp to $7.4 million (FY25: $9.5 million), down 19% in CC. The decline in spare parts is a positive signal of fleet modernisation as customers transition to newer generation trophon systems. 80.4 92.2 92.6 96.2 11.8 15.1 15.8 16.0 24.0 29.4 33.4 34.8 116.2 136.7 141.8 147.1 FY24 FY25 FY26 FY26 CC Core Consumables Ecosystem Service 1. Annuity Revenue is Recurring Revenue excluding spare parts and was adopted in FY26 as a key corporate and STI metric. 8% growth on pcp in CC 4% growth on pcp Annuity Revenue (Recurring Revenue, excluding spare parts)
Page 14
Record North American adoption, with upgrades up 32% Cumulative Installed Base Upgrades 14 • Cumulative installed base has grown 6% to 34,210, expanding the Annuity Revenue foundation. • 1,900 new installed base units added, comparable to FY25 (1,920). • 1,980 upgrade units placed, up 32% on pcp. • North America is the primary upgrade market, with approximately 8,000 original EPR devices conversion opportunity still remaining. 1,300 1,500 1,980 FY24 FY25 FY26 Total Placements • Record annual total placements of 3,880 units, up 13% on pcp. 3,300 3,420 3,880 FY24 FY25 FY26 (Devices) Graphs are not to scale and therefore not comparable. (Devices) (Devices) 30,390 32,310 34,210 FY24 FY25 FY26 6% growth on pcp 32% growth on pcp 13% growth on pcp
Page 15
103.7 121.7 126.8 132.2 45.0 49.4 52.3 54.3 5.5 9.3 7.3 7.6 154.2 180.4 186.4 194.2 FY24 FY25 FY26 FY26 CC Annuity Capital Spare parts 8% North America Revenue growth in constant currency Revenue Annuity Revenue (Annuity revenue = Recurring Revenue, excluding spare parts) 15 • $186.4 million in Reported Revenue, up 3%, or 8% growth at CC. • $52.3 million in Capital Revenue, up 6%, or 10% at CC. • Spare parts revenue was $7.3 million, down 21%, or down 18% in CC. • $126.8 million in Annuity Revenue, up 4% on pcp, or 9% at CC. 72.2 82.3 83.0 86.7 10.8 13.6 14.4 14.6 20.7 25.7 29.4 31.0 103.7 121.7 126.8 132.2 FY24 FY25 FY26 FY26 CC Core Consumables Ecosystem Service Graphs are not to scale and therefore not comparable. ($M) ($M) 3% growth on pcp 8% growth on pcp in CC 4% growth on pcp 9% growth on pcp in CC
Page 16
8.3 10.1 10.8 1.8 2.0 1.5 10.1 12.2 12.3 FY24 FY25 FY26 Annuity Capital Spare parts 4.2 4.9 4.2 1.5 1.1 0.9 5.8 6.0 5.1 FY24 FY25 FY26 Annuity Capital Spare parts Continuing cumulative installed base growth in EMEA & APAC Cumulative Installed Base Revenue Cumulative Installed Base Revenue 16 • EMEA revenue $12.3M, up 1% on pcp, moderated 1% in CC. • Annuity Revenue up 7% on pcp, or 6% up at CC. • Capital Revenue moderation, reflects mix change to more MES purchase model1 with no upfront capital component. • APAC Cumulative IB has grown 6% to 2,390 units. • 130 new installed base units added, up 44% on pcp. • Majority of EPR units already upgraded. • Cumulative IB has grown 8% to 2,630 units. • 200 new installed base, flat on pcp. • Majority of original trophon EPR units are already upgraded. • APAC revenue of $5.1 million, moderated 14% on pcp. • Annuity Revenue moderated 13%. • Capital Revenue moderation reflects greater rental mix in Japan. 2,230 2,430 2,630 FY24 FY25 FY26 2,170 2,260 2,390 FY24 FY25 FY26 EMEA Cumulative Installed Base grows 8% on pcp APAC Cumulative Installed Base grows 6% on pcp Graphs are not to scale and therefore not comparable. Spare parts are not meaningful in EMEA & APAC. 1. MES is a Managed Equipment Services purchase model which is prominent in the UK. (Devices) (Devices) ($M) ($M) 1% Growth on pcp -14% on pcp
Page 17
Cost discipline supports 21% EBIT growth at constant currency Gross Profit Operating Expenses Earnings before interest and taxes 17 • Gross Profit of 76.9%, down 1.3pts largely driven by foreign exchange and product mix. At constant currency, Gross profit was 77.6%. • $2.5 million of US tariffs recovered for the period to February 2026, leaving residual FY26 tariffs of $0.6 million, broadly flat on FY25 ($0.5 million). • Operating expense growth held to 2% (4% in CC) to $141.4 million. • trophon: $106.8 million, down 1% on pcp. • CORIS: $34.6 million, up 13% on pcp. • Reflects disciplined cost control while continuing to invest in growth initiatives. • EBIT of $16.0 million, down 10% on pcp. • EBIT at CC of $21.6 million, up 21%. 98.2 108.1 106.8 109.1 27.4 30.6 34.6 34.8 125.6 138.7 141.4 143.9 FY24 FY25 FY26 FY26 CC trophon CORIS 1% DECLINE ON PCP 13% GROWTH ON PCP 1% GROWTH ON PCP IN CC 14% GROWTH ON PCP IN CC Graphs are not to scale and therefore not comparable. -10% on pcp 21% growth on pcp in CC 2% growth on pcp 4% growth on pcp in CC -1.3 ppts on pcp -0.6 ppts on pcp in CC ($M) ($M) (%) 9.1 17.8 16.0 21.6 FY24 FY25 FY26 FY26 CC 77.9% 78.2% 76.9% 77.6% FY24 FY25 FY26 FY26 CC
Page 18
Strong cash position • $155.2 million in cash and cash equivalents, with no debt. • $13.6 million of business cash flow generated, reflecting cash generation from the trophon business, while funding CORIS. • $20 million share buyback completed in FY26, with a further buyback of up to $40 million announced for FY27. • Net cash outflow of $6.4 million reflects the buyback and a deliberate increase in inventory to support growth in trophon and the launch of CORIS. • Debt-free, with the capacity to fund the CORIS investment step-up, continued innovation and shareholder returns simultaneously. FY25 to FY26 cash flow bridge$13.6M business cash flow1 $155.2M cash & cash equivalents 1. Business cash flows = cash flow – share buyback Graphs are not to scale and therefore not comparable. ($M) $155.2 million in cash and debt free, with capacity to invest and return capital. 161.6 13.6 -20.0 155.2 FY25 Cash Balance Business cash flow Share buyback FY26 Cash Balance 18
Page 19
Strategic Growth In Ultrasound Reprocessing 19
Page 20
20 Nanosonics pioneered the trophon® device, a unique automated high-level disinfection technology for ultrasound probes. It offers unmatched probe compatibility: 1,400+ probes across 31 leading manufacturers, each tested and validated. No solution on the market has broader efficacy. That’s how Nanosonics is setting the global infection prevention standard. The global experts in ultrasound probe reprocessing.
Page 21
Next generation technology launched Cumulative installed base expanded Upgrades accelerated Operating leverage and cash generation trophon momentum Achievements Ahead 21 Continued installed base growth trophon3 and trophon2 Plus upgrade momentum Consumables & service expansion Continued operating leverage
Page 22
trophon earnings strength funds future growth 22 • Reported Revenue $203.9 million, of up 3% on pcp. • At constant currency, Revenue was $211.5 million, up 6%. • Operating expenses of $106.8 million, down 1% on pcp, or up 1% at CC. • EBIT of $50.6 million, up 5% on pcp, or $56.6 million up 16% at CC. • Operating income before income tax of $54.7 million, up 4% on pcp, or up 14% at CC. $ millions FY26 Reported FY25 Reported % growth Reported % growth at CC Capital revenue 54.7 52.5 4% 8% Recurring revenue 149.2 146.1 2% 6% Total revenue 203.9 198.6 3% 6% Gross profit 156.8 155.4 1% 6% Gross profit % 76.9% 78.2% -1.3 pts Operating expenses Selling, general and administration 96.5 95.7 1% Research and development 10.3 12.4 -17% Total Operating expenses 106.8 108.1 -1% 1% Operating margin 50.0 47.2 6% 16% Other income 1.5 1.3 19% Other gains/(losses)-net (0.9) (0.1) nm* Earnings before interest and tax 50.6 48.4 5% 16% Finance income-net 4.1 4.5 -8% Operating income before income tax 54.7 52.8 4% 14% Demonstrates the core franchise’s earnings power, cash generation and expanding operating leverage. trophon-only Profit & Loss *nm = not meaningful comparison 1. The pro forma profit before tax for the trophon business is unaudited and has been prepared by management to reflect total Company results less operating costs associated with new product development and commercialisation for CORIS. Operating costs reflect management allocation estimates where resources are shared between trophon and CORIS development and commercialisation. The pro forma profit and loss statement also includes income received from the Jobs Plus Program. Methodology has been subjected to an agreed procedure review by external auditors.
Page 23
Initial installation Upgrade Year 1 2 3 4 5 6 7 8 CAPITAL RECURRING A multi-lever strategy for continued trophon growth Seven growth levers across capital and recurring revenue. CAPITAL REVENUE 01 New installed base device sales, trophon3 02 Upgrade capital sales 03 Capital software upgrades, trophon2 Plus RECURRING REVENUE 04 Core consumables 05 Ecosystem consumables 06 Service 07 Connectivity subscriptions Software upgrades – trophon2 Plus opportunity Lifecycle value opportunity of a trophon unit. LEVERS 01–03 LEVERS 04–07 23 Service from year 2Ongoing consumables
Page 24
Transforming Endoscope Reprocessing 24
Page 25
25 Transforming flexible endoscope reprocessing. The Nanosonics CORIS® System introduces a groundbreaking approach to cleaning the internal channels of flexible endoscopes, delivering consistent, validated and traceable outcomes. Powered by CORIS PULSS (Pulsed Suspended Solids) technology, it delivers controlled physical friction to help remove soil and biofilm, including areas that are difficult or impossible to access with conventional methods.
Page 26
26 01 Groundbreaking technology Automated technology setting a new benchmark in patient safety. 02 60 million procedure TAM1 Substantial underserved market, with strong fundamentals for adoption. 03 Attractive business model Attractive recurring revenue model and proven commercial capability. 04 Commercialisation pathway Investment to accelerate market awareness, generate customer pipeline and drive initial adoption. The CORIS System: a substantial opportunity launching in H1 FY27 1. References on file; available upon request 26
Page 27
A critical cleaning step, manual methods cannot reliably complete Cleaning is the critical first step in reprocessing flexible endoscopes, yet it remains manual, variable and unverified. The CORIS System automates it. THE PROBLEM Manual cleaning cannot reach every channel Unreachable channels Narrow and branched channels are difficult or impossible to brush and flushing alone may not remove contamination. Biofilm persists Contamination and biofilm can remain inside channels even when protocols are followed, creating patient safety risk. Variable and unverified Outcomes vary between individuals, shifts and workloads, with documentation covering only selected steps. THE SOLUTION The CORIS System automates and verifies the cleaning step A new benchmark in efficacy Delivers the physical friction required to remove soil and biofilm from narrow, branched and unbrushable channels. Engineered for consistency Standardises a critical step, reducing variability and supporting repeatable outcomes across every site. Traceable every cycle Captures validated cleaning parameters for each cycle, supporting verification and audit readiness. CORIS automates the one step in endoscope reprocessing that has remained manual, variable and unverified. Protects reprocessing teams Designed to reduce physical burden and exposure to chemicals and infectious materials via an automated, closed system workflow. Smarter Workflows Minimises labour-intensive manual steps, helping teams to focus on quality, compliance and other essential tasks. 27
Page 28
Entering commercial launch in H1 FY27 Real world CMR experience Early clinical utility supported Positive feedback with strong confidence in consistent cleaning, with further and clinical data opportunities identified. “The team will be queuing up to use the CORIS System. It will be run every minute of the day. Looks super impressive and extremely easy to use.” Decontamination Supervisor, CMR site Phased launch plan >2M AUSTRALIA >5M UNITED KINGDOM & IRELAND >34M UNITED STATES Note: All new product development programs involve inherent risks and uncertainties which can impact commercialisation timelines. 1. References on file; available upon request. “Incredible enhancement for endoscope reprocessing and improving patient safety.” Infection prevention and compliance expert procedure opportunity procedure opportunity procedure opportunity 28 H1 FY27 H2 FY27 >60M procedural TAM1 across key regions
Page 29
Five CMR sites live across four markets 03 Ireland 04 United Kingdom01 Australia 29 02 United States Australia and the UK commenced in H2 FY26, with further sites now active in Ireland, the United States and Australia.
Page 30
Every CORIS installation builds recurring value Capital, consumables and service compound as the installed base grows, leveraging the same annuity model as trophon. 01 CAPITAL & ACCESSORIES 3-5X TROPHON capital price Mix of capital sales and other selling models. + 02 UTILISATION ~10 cycles per device per day High volume sites may have 3-4 units in Central Sterile Department. + 03 CONSUMABLES 4-6X TROPHON price per cycle Price will vary based on purchase model & market. + 04 SERVICE ~80% attachment rate Customer opt-in, expected to be high post 1 year warranty. Indicative metrics are early stage estimates, subject to change as commercial experience builds. 3030
Page 31
Stepping up FY27 CORIS investment for launch Build commercial capacity to drive demand • CORIS sales specialists, clinical, installation and support teams in market • Build awareness and pipeline • Establish first flagship reference sites • Expanded Clinical data to further reinforce value proposition FY27 is a launch year for CORIS: 20-30 customer sites targeted and revenue expected in the low single digit millions, with the return delivered through accelerating installed base growth and recurring revenue in subsequent years. Disciplined use of a strong balance sheet for long-term shareholder value creation. Commercial launch in the UK, Ireland and Australia in H1 FY27, with the US to follow. 31 FY27 is the launch year for CORIS focusing on establishing broad market awareness, pipeline build and initial customer/reference site adoption. Targeting low single digit millions revenue.
Page 32
Outlook & Guidance 32
Page 33
Gross Profit % Revenue FY27 Outlook 33 • Customer demand for trophon is expected to continue into FY27, driving capital and recurring revenue. • CORIS expected to contribute initial revenues in the low single digit millions. $220 million to $228 million, reflecting 8% to 12% growth on FY26. FY27 guidance at constant currency 74%-76% Operational expenses $156 million to $163 million, reflecting 10% to 15% growth on FY26. Nanosonics enters FY27 with strong momentum, forecasting Revenue growth of 8% to 12% at constant currency, while stepping up investment in the CORIS System. Notes & assumptions • Gross Profit % expected to moderate due to the impact of a full 12 months of tariffs at rate of 12.5%. Freight costs also higher due to increased volume and price increases resulting from geo-political impacts. Guidance is at constant currency, using a USD/AUD exchange rate of 0.68. Nanosonics generates the majority of its revenue in USD and notes the continued strengthening Australian dollar.If the Revenue range in the above table were recast using an average exchange rate for USD/AUD of 0.71 FY27, rather than constant currency, and the hedging program is taken into account, the Revenue range would be approximately $3 million lower. Guidance assumes no changes to the global trading environment and US tariffs at current level of 12.5%. All guidance is subject to uncertainty in relation to potential impacts associated with macroeconomic and political uncertainty, as well as potential impacts from increased competitive activity in the USA. • Operational expenses expected to increase as the Company deliberately increases investment to support the CORIS System launch. • Majority of opex growth relates to CORIS. Operating leverage improvements are expected to continue in trophon-only business.
Page 34
Launching a $40 million share buyback On-market buyback of up to $40 million in FY27, alongside continued investment in trophon and the CORIS launch. Balance sheet strength to invest and return capital. 34 Note: The share buyback will impact interest earned and cash balance. The program may be varied, suspended, or terminated at any time depending on market conditions, share price, operational performance, and alternative capital deployment opportunities.
Page 35
Appendices 35
Page 36
Income tax & constant currency disclosure • Effective income tax for the period was 11% (FY25 7%) • Assessment of probability of recovery (and therefore recognition of related benefit) of unrecognised losses is made on an on-going basis. • Currently Nanosonics has $12.4m in unrecognised losses. Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance. This is done by (1) converting the current year sales, costs and operating expenses of entities that use currencies other than Australian dollars at the average rates that were applicable in the prior year (2) restating foreign currency denominated transactions of the parent entity that is impacted by exchange rate movements at the average rates that were applicable in the prior year and (3) by adjusting for foreign currency gains and losses. The average exchange rate used for the Company's major foreign currency (USD) for FY26 was 0.68 (FY25: 0.65). *Constant currency revenue, EBIT and PBT have not been audited or reviewed in accordance with Australian Auditing Standards. Income tax Constant currency comparison $ millions FY26 FY25 Income tax expense 2.3 1.6 Components of Net Deferred Tax Asset 30-Jun-26 30-Jun-25 Tax losses 0.1 0.5 R&D tax credits 0.9 - All other timing differences 16.9 18.4 Total 17.9 18.9 Value of carried forward losses & R&D credits Gross Tax Benefit Effective rate % Losses recognised 0.3 0.1 33.3% R&D credits carried forward 3.0 0.9 30.0% Total losses and R&D credits recognised 3.3 1.0 30.3% Losses not recognised 12.4 4.3 34.7% Total 15.7 5.3 33.8% Summary Revenue FY26 FY25 Change % Reported revenue 203.9 198.6 3% Currency effect (1 & 2) 7.6 Constant currency revenue* 211.5 198.6 6% Summary EBIT FY26 FY25 Change % Reported EBIT 16.0 17.8 -10% Currency effect (1 & 2) 4.7 Currency effect (3) 0.9 0.1 Constant currency EBIT* 21.6 17.9 21% Summary Profit before tax FY26 FY25 Change % Reported profit before tax 20.1 22.3 -10% Currency effect (1 & 2) 4.8 Currency effect (3) 0.9 0.1 Constant currency profit before tax* 25.8 22.4 15% 36
Page 37
Disclaimer 37 This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation. Certain information may relate to protected intellectual property rights owned by Nanosonics Limited (Nanosonics) and its subsidiaries (together the Group). While due care has been taken in compiling the information based on the information available to Nanosonics at the date of this presentation material, neither Nanosonics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group. The information does not constitute advice of any kind and should not be relied on as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for their own investment purposes. Any and all use of the information is at your own risk. No representation, warranty or assurance (express or implied) is given or made in relation to any forward looking statement or estimate by any person (including Nanosonics). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Nanosonics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations in relation to any forward looking statements or any change in events, conditions or circumstances on which any such statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Group since the date of these materials. trophon®, CORIS® and Nanosonics Connect® are registered trade marks of Nanosonics Limited.